EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration

Jinfeng Wang, Xiaoxiao Wang, Jianfei Shi, Yongjun Wang, Lili Mi, Man Zhao, Guangjie Han, Fei Yin

PeerJ · 17.03.2025 · 13 · e19055

DOI: 10.7717/peerj.19055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, online erschienen am 17.03.2025. Verfasst von Jinfeng Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, NK Cell Lectin-Like Receptor Subfamily B. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Natural Science Foundation, Medical Science Research Project of Hebei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD161, encoded by the killer cell lectin-like receptor B1 ( KLRB1 ) gene, exhibits varied roles among different tumors. This study aimed to explore both the potential value of CD161 as a prognostic biomarker for hepatocellular carcinoma (HCC) and its association with immune cell infiltration.

Methods

A total of 109 HCC patients who underwent surgery were retrospectively analyzed. Immunohistochemistry, bioinformatic analyses, and statistical measurements were used to investigate the associations between CD161 expression, immune cell infiltration, and clinical outcomes in both public databases and in-house cohorts.

Results

CD161 was highly expressed at both protein and mRNA levels in adjacent normal tissues compared to tumor tissues of HCC patients. Meanwhile, CD161 was enriched in HCC cases characterized by smaller tumor sizes (≤5 cm) and the absence of portal vein tumor thrombus. Individuals with high CD161 expression showed extended overall survival (OS) and relapse free survival (RFS) compared to those with lower CD161 levels. CD161 was identified as an independent prognostic indicator for both OS and RFS. In addition, the enrichment analysis indicated a close correlation between CD161 and immune response, as well as between CD161 and the signaling pathways of cytokines and chemokines, implying its role in immune regulation during cancer development. Specifically, CD161 expression was positively associated with immunomodulators and tumor-infiltrating immune cells, especially CD8+T cells, CD4+T cells, and dendritic cells. Multiple public databases showed that patients with high CD161 expression were more likely to derive benefits from immunotherapy.

Conclusion

CD161 was identified as a promising prognostic biomarker for HCC, as its expression indicates a favorable prognosis. Additionally, CD161 is closely linked to high infiltration of immune cells, participates in the regulation of the tumor immune microenvironment, and holds promise as a potential biomarker for predicting the efficacy of immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorNK Cell Lectin-Like Receptor Subfamily BHumansMaleFemalePrognosisMiddle AgedRetrospective StudiesAged

Stichwörter der Autor:innen

CD161Hepatocellular carcinomaImmune infiltrationImmunotherapyPrognostic biomarkerTumor immune microenvironment

Substanzen

Biomarkers, TumorNK Cell Lectin-Like Receptor Subfamily B

Autor:innen und Institutionen

  • Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Förderung

  • Hebei Natural Science Foundation
  • Medical Science Research Project of Hebei

Zitieren

APA

Wang, J., Wang, X., Shi, J., Wang, Y., Mi, L., Zhao, M., Han, G., & Yin, F. (2025). CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration. PeerJ, 13, e19055. https://doi.org/10.7717/peerj.19055

Vancouver

Wang J, Wang X, Shi J, Wang Y, Mi L, Zhao M, et al. CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration. PeerJ. 2025;13:e19055. doi:10.7717/peerj.19055

BibTeX
@article{Wang2025,
  author = {Wang, Jinfeng and Wang, Xiaoxiao and Shi, Jianfei and Wang, Yongjun and Mi, Lili and Zhao, Man and Han, Guangjie and Yin, Fei},
  title = {CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration},
  journal = {PeerJ},
  year = {2025},
  volume = {13},
  pages = {e19055},
  doi = {10.7717/peerj.19055}
}
Kostenlos starten →